Literature DB >> 19435902

Lack of T-cell receptor-induced signaling is crucial for CD95 ligand up-regulation and protects cutaneous T-cell lymphoma cells from activation-induced cell death.

Claus-Detlev Klemke1, Dirk Brenner, Eva-Maria Weiss, Marc Schmidt, Martin Leverkus, Karsten Gülow, Peter H Krammer.   

Abstract

Restimulation of previously activated T cells via the T-cell receptor (TCR) leads to activation-induced cell death (AICD), which is, at least in part, dependent on the death receptor CD95 (APO-1, FAS) and its natural ligand (CD95L). Here, we characterize cutaneous T-cell lymphoma (CTCL) cells (CTCL tumor cell lines and primary CTCL tumor cells from CTCL patients) as AICD resistant. We show that CTCL cells have elevated levels of the CD95-inhibitory protein cFLIP. However, cFLIP is not responsible for CTCL AICD resistance. Instead, our data suggest that reduced TCR-proximal signaling in CTCL cells is responsible for the observed AICD resistance. CTCL cells exhibit no PLC-gamma1 activity, resulting in an impaired Ca(2+)release and reduced generation of reactive oxygen species upon TCR stimulation. Ca(2+) and ROS production are crucial for up-regulation of CD95L and reconstitution of both signals resulted in AICD sensitivity of CTCL cells. In accordance with these data, CTCL tumor cells from patients with Sézary syndrome do not up-regulate CD95L upon TCR-stimulation and are therefore resistant to AICD. These results show a novel mechanism of AICD resistance in CTCL that could have future therapeutic implications to overcome apoptosis resistance in CTCL patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19435902     DOI: 10.1158/0008-5472.CAN-08-4631

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Silencing autocrine death: a ubiquitin ligase that blocks activation-induced cell death in cutaneous T-cell lymphoma.

Authors:  Claus-Detlev Klemke; Maria Feoktistova; Martin Leverkus
Journal:  J Invest Dermatol       Date:  2015-03       Impact factor: 8.551

Review 2.  Cutaneous T-cell lymphomas: a review of new discoveries and treatments.

Authors:  Tara Bloom; Timothy M Kuzel; Christiane Querfeld; Joan Guitart; Steven T Rosen
Journal:  Curr Treat Options Oncol       Date:  2012-03

3.  Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.

Authors:  Salvia Jain; Dina Stroopinsky; Li Yin; Jacalyn Rosenblatt; Maroof Alam; Parul Bhargava; Rachael A Clark; Thomas S Kupper; Kristen Palmer; Maxwell D Coll; Hasan Rajabi; Athalia Pyzer; Michal Bar-Natan; Katarina Luptakova; Jon Arnason; Robin Joyce; Donald Kufe; David Avigan
Journal:  Blood       Date:  2015-06-05       Impact factor: 22.113

4.  Aurora Kinase A Is Upregulated in Cutaneous T-Cell Lymphoma and Represents a Potential Therapeutic Target.

Authors:  Daniel Humme; Ahmed Haider; Markus Möbs; Hiroshi Mitsui; Mayte Suárez-Fariñas; Hanako Ohmatsu; Cyprienne Isabell Geilen; Jürgen Eberle; James G Krueger; Marc Beyer; Michael Hummel; Ioannis Anagnostopoulos; Wolfram Sterry; Chalid Assaf
Journal:  J Invest Dermatol       Date:  2015-04-07       Impact factor: 8.551

5.  Loss of nuclear pro-IL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma.

Authors:  Clara Curiel-Lewandrowski; Hisato Yamasaki; Chuan Ping Si; Xiaoyi Jin; Yujun Zhang; Jillian Richmond; Marina Tuzova; Kevin Wilson; Beth Sullivan; David Jones; Nataliya Ryzhenko; Frederick Little; Thomas S Kupper; David M Center; William W Cruikshank
Journal:  J Clin Invest       Date:  2011-11-14       Impact factor: 14.808

6.  Programmed cell death-10 enhances proliferation and protects malignant T cells from apoptosis.

Authors:  Britt Lauenborg; Katharina Kopp; Thorbjørn Krejsgaard; Karsten W Eriksen; Carsten Geisler; Sally Dabelsteen; Robert Gniadecki; Qian Zhang; Mariusz A Wasik; Anders Woetmann; Niels Odum
Journal:  APMIS       Date:  2010-08-19       Impact factor: 3.205

7.  c-CBL E3 Ubiquitin Ligase Expression Increases Across the Spectrum of Benign and Malignant T-Cell Skin Diseases.

Authors:  Katrin A Salva; Margo J Reeder; Rita Lloyd; Gary S Wood
Journal:  Am J Dermatopathol       Date:  2017-10       Impact factor: 1.533

8.  Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma.

Authors:  Salvia Jain; Abigail Washington; Rebecca Karp Leaf; Parul Bhargava; Rachael A Clark; Thomas S Kupper; Dina Stroopinsky; Athalia Pyzer; Leandra Cole; Myrna Nahas; Arie Apel; Jacalyn Rosenblatt; Jon Arnason; Donald Kufe; David Avigan
Journal:  Mol Cancer Ther       Date:  2017-07-20       Impact factor: 6.261

9.  Versican upregulation in Sézary cells alters growth, motility and resistance to chemotherapy.

Authors:  K Fujii; M B Karpova; K Asagoe; O Georgiev; R Dummer; M Urosevic-Maiwald
Journal:  Leukemia       Date:  2015-04-27       Impact factor: 11.528

Review 10.  Lessons learned from gene expression profiling of cutaneous T-cell lymphoma.

Authors:  B O Dulmage; L J Geskin
Journal:  Br J Dermatol       Date:  2013-12       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.